Nevertheless, with expanding clinical adoption of PARP inhibitors in first-line maintenance regimens for ovarian cancer, the emergence of acquired resistance has become a critical clinical barrier requiring urgent resolution. This evidence concerns the gene PARP1 and ovarian cancer.